UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-09974 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) | --- | --- | --- | |-------- ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2022 was $26.2 million, a decrease of 20% from $32.8 million in Q3 2021, attributed to declining COVID-19 testing volumes and economic shutdowns in Asia [29][30] - Enzo Clinical Lab Service revenue was $18.6 million, down 26% from $25 million in the same quarter last year, although routine testing revenue increased by 10% [30] - Enzo Life Sciences revenue was $7.6 million, slightly down year-over-year but up 9% year-to-date, indicating stability in the customer base [32] Business Line Data and Key Metrics Changes - Enzo Clinical Lab's non-COVID revenue increased by 3% year-over-year, demonstrating recovery in core testing [30] - The company added 43 new tests in Q3, totaling 126 new tests year-to-date, focusing on specialty testing [31] - Enzo Life Sciences faced challenges due to economic shutdowns in Asia and supply chain issues in Europe, but anticipates overall annual growth of 10% for fiscal year 2022 [32] Market Data and Key Metrics Changes - The blended gross margin for the quarter declined to 39% from 49% year-over-year, impacted by both Enzo Clinical Lab and Enzo Life Sciences [33] - Enzo Clinical Lab's margin decreased from 49% to 40% due to reduced higher-margin COVID tests, while Life Sciences gross margin fell to 36% due to increased manufacturing costs [33][34] Company Strategy and Development Direction - The company is focused on a corporate structure that supports three separate businesses: Enzo Life Sciences, Enzo Clinical Labs, and Enzo Diagnostics, which allows for synergies and tailored solutions [12][11] - Enzo is committed to investing in technology and strategic partnerships to accelerate growth in core life sciences and clinical lab businesses [19] - The company is preparing to launch new diagnostic platforms and has received approvals for several molecular tests, indicating a strong focus on expanding its diagnostic capabilities [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic vision and ability to execute on growth initiatives, particularly in Life Sciences and Diagnostic platforms [40][28] - The company is exploring strategic alternatives with the help of Jefferies LLC, indicating a proactive approach to enhancing shareholder value [39][28] Other Important Information - Cash and cash equivalents totaled $32.1 million as of April 30, 2022, down from $44.3 million at the end of fiscal year 2021, due to various strategic initiatives [37] - The company maintains a goal of achieving an additional $10 million in cost savings, with $5 million targeted for calendar year 2022 [38] Q&A Session Summary Question: Clarification on the Jefferies process and its differences from the prior process - Management indicated that they are not making public comments on the specifics but are picking up where they left off in the previous process [42]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-09974 ENZO BIOCHEM, INC. | --- | --- | |-------------------------------------------------- ...

Enzo Biochem, Inc. (NYSE:ENZ) Q2 2022 Earnings Conference Call March 14, 2022 4:30 PM ET Company Participants David Holmes - Investor Relations Hamid Erfanian - Chief Executive Officer David Bench - Chief Financial Officer Conference Call Participants Paul Nouri - Noble Equity Fund Christian Schwab - Craig Hallum Kenan Lucas - Harbert Management Corporation Dan Weston - WestCap Management Operator Greetings. And welcome to the Enzo Biochem Second Quarter 2022 Financial Results and Business Update Conferenc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-09974 ENZO BIOCHEM, INC. | --- | --- | |------------------------------------------------ ...

Enzo Biochem, Inc. (NYSE:ENZ) Q1 2022 Results Conference Call December 15, 2021 4:30 PM ET Company Participants David Holmes - LifeSci Advisors IR Hamid Erfanian - CEO David Bench - CFO Conference Call Participants Paul Nouri - Noble Equity Fund Operator Greetings. Welcome to the Enzo Biochem First Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-09974 ENZO BIOCHEM, INC. | --- | --- | |------------------------------------------------ ...

Enzo Biochem, Inc. (NYSE:ENZ) Q4 2021 Results Earnings Conference Call October 12, 2021 8:30 AM ET Company Participants Bob Yedid - LifeSci Advisors, LLC Barry Weiner - Co-Founder and President David Bench - Chief Financial Officer Conference Call Participants Paul Nouri - Noble Equity Fund Operator Greetings. And welcome to the Enzo Biochem Fourth Quarter and Full Year 2021 Financial Results and Business Update. At this all participants are in a listen-only mode. A question and answer session will follow t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-09974 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) | --- | --- | --- | |-------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-09974 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) | --- | --- | --- | |- ...